DJIA 17,113.54 61.81 0.36%
NASDAQ 4,456.02 31.31 0.71%
S&P 500 1,983.53 9.90 0.50%
market minute promo

ULTRAGENYX PHARMAC (NASDAQ: RARE)

42.97 -0.27 (-0.62%)

Quote as of

Extended Hours: $43.02 $0.05 (0.11%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

RARE $42.97 -0.62%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $43.37
Previous Close $43.24
Daily Range $42.58 - $43.73
52-Week Range $32.02 - $69.77
Market Cap $1.3B
P/E Ratio -3.36
Dividend (Yield) $0.00 (0.0%)
Volume 139,203
Average Daily Volume 273,010
Current FY EPS -$2.12

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

News & Commentary Rss Feed

Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape

3 Biotech Stocks Breaking Out With Big Volume

InsiderInsights.com Daily Round Up: 7/14/14

Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape

Sector Update: Health Care

Sector Update: Health-Care Shares Flat Pre-Market

US Stock Futures Flat; All Eyes On Fed Minutes

Tuesday Sector Laggards: Biotechnology, Drugs

Ultragenyx Announces Initiation Of A Phase 2 Study of KRN23 For Pediatric X-Linked Hypophosphatemia

Ultragenyx Announces Initiation Of A Phase 2 Study of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU

Ultragenyx Announces Results From Phase 1/2 Study Involving KRN23 In X-Linked Hypophosphatemia In Ad

Ultragenyx Announces Results From Phase 1/2 Study Involving KRN23 In X-Linked Hypophosphatemia In Adults

See More RARE News...